T1	Participants 89 145	patients with locally advanced resectable rectal cancer.
T2	Participants 363 394	Patients with stage II/III LARC
T3	Participants 873 908	Thirty-seven patients were eligible
T4	Participants 1348 1359	17 patients
T5	Participants 1469 1480	13 patients
T6	Participants 1527 1537	6 patients
T7	Participants 1687 1717	patients with resectable LARC.
